Proteasome inhibition interferes with Gag polyprotein processing, release, and maturation of HIV-1 and HIV-2

被引:264
作者
Schubert, U
Ott, DE
Chertova, EN
Welker, R
Tessmer, U
Princiotta, MF
Bennink, JR
Kräusslich, HG
Yewdell, JW
机构
[1] NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA
[2] NCI, Sci Applicat Int Corp, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA
[3] Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany
关键词
D O I
10.1073/pnas.97.24.13057
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Retrovirus assembly and maturation involve folding and transport of viral proteins to the virus assembly site followed by subsequent proteolytic cleavage of the Gag polyprotein within the nascent virion. We report that inhibiting proteasomes severely decreases the budding, maturation, and infectivity of HIV. Although processing of the Env glycoproteins is not changed, proteasome inhibitors inhibit processing of tag polyprotein by the viral protease without affecting the activity of the HIV-1 viral protease itself, as demonstrated by in vitro processing of HIV-1 tag polyprotein Pr55. Furthermore, this effect occurs independently of the virus release function of the HIV-1 accessory protein Vpu and is not limited to HIV-1, as proteasome inhibitors also reduce virus release and tag processing of HIV-2. Electron microscopy analysis revealed ultrastructural changes in budding virions similar to mutants in the late assembly domain of p6(gag), a C-terminal domain of Pr55 required for efficient virus maturation and release. Proteasome inhibition reduced the level of free ubiquitin in HIV-1-infected cells and prevented monoubiquitination of p6(gag). Consistent with this, viruses with mutations in PR or p6(gag) were resistant to detrimental effects mediated by proteasome inhibitors. These results indicate the requirement for an active proteasome/ubiquitin system in release and maturation of infectious HIV particles and provide a potential pharmaceutical strategy for interfering with retrovirus replication.
引用
收藏
页码:13057 / 13062
页数:6
相关论文
共 25 条
[1]   PRODUCTION OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED RETROVIRUS IN HUMAN AND NONHUMAN CELLS TRANSFECTED WITH AN INFECTIOUS MOLECULAR CLONE [J].
ADACHI, A ;
GENDELMAN, HE ;
KOENIG, S ;
FOLKS, T ;
WILLEY, R ;
RABSON, A ;
MARTIN, MA .
JOURNAL OF VIROLOGY, 1986, 59 (02) :284-291
[2]   THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VPU PROTEIN SPECIFICALLY BINDS TO THE CYTOPLASMIC DOMAIN OF CD4 - IMPLICATIONS FOR THE MECHANISM OF DEGRADATION [J].
BOUR, S ;
SCHUBERT, U ;
STREBEL, K .
JOURNAL OF VIROLOGY, 1995, 69 (03) :1510-1520
[3]   INHIBITION OF PROTEASOME ACTIVITIES AND SUBUNIT-SPECIFIC AMINO-TERMINAL THREONINE MODIFICATION BY LACTACYSTIN [J].
FENTEANY, G ;
STANDAERT, RF ;
LANE, WS ;
CHOI, S ;
COREY, EJ ;
SCHREIBER, SL .
SCIENCE, 1995, 268 (5211) :726-731
[4]   EFFECT OF MUTATIONS AFFECTING THE P6 GAG PROTEIN ON HUMAN-IMMUNODEFICIENCY-VIRUS PARTICLE RELEASE [J].
GOTTLINGER, HG ;
DORFMAN, T ;
SODROSKI, JG ;
HASELTINE, WA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (08) :3195-3199
[5]   The ubiquitin system [J].
Hershko, A ;
Ciechanover, A .
ANNUAL REVIEW OF BIOCHEMISTRY, 1998, 67 :425-479
[6]  
HOU D, 1994, J BIOL CHEM, V269, P14244
[7]   P6(GAG) IS REQUIRED FOR PARTICLE-PRODUCTION FROM FULL-LENGTH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 MOLECULAR CLONES EXPRESSING PROTEASE [J].
HUANG, MJ ;
ORENSTEIN, JM ;
MARTIN, MA ;
FREED, EO .
JOURNAL OF VIROLOGY, 1995, 69 (11) :6810-6818
[8]   THE ACTIVITY OF THE PROTEASE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IS INITIATED AT THE MEMBRANE OF INFECTED-CELLS BEFORE THE RELEASE OF VIRAL-PROTEINS AND IS REQUIRED FOR RELEASE TO OCCUR WITH MAXIMUM EFFICIENCY [J].
KAPLAN, AH ;
MANCHESTER, M ;
SWANSTROM, R .
JOURNAL OF VIROLOGY, 1994, 68 (10) :6782-6786
[9]   THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1-SPECIFIC PROTEIN VPU IS REQUIRED FOR EFFICIENT VIRUS MATURATION AND RELEASE [J].
KLIMKAIT, T ;
STREBEL, K ;
HOGGAN, MD ;
MARTIN, MA ;
ORENSTEIN, JM .
JOURNAL OF VIROLOGY, 1990, 64 (02) :621-629
[10]   AN ACTIVE-SITE MUTATION IN THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEINASE (PR) CAUSES REDUCED PR ACTIVITY AND LOSS OF PR-MEDIATED CYTOTOXICITY WITHOUT APPARENT EFFECT ON VIRUS MATURATION AND INFECTIVITY [J].
KONVALINKA, J ;
LITTERST, MA ;
WELKER, R ;
KOTTLER, H ;
RIPPMANN, F ;
HEUSER, AM ;
KRAUSSLICH, HG .
JOURNAL OF VIROLOGY, 1995, 69 (11) :7180-7186